Send to

Choose Destination
Br J Haematol. 2019 May;185(3):503-513. doi: 10.1111/bjh.15803. Epub 2019 Feb 21.

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.

Author information

Department of Hematology, Massachusetts General Hospital, Boston, MA, USA.
The Pathology Clinical Academic Group, the Royal London Hospital, London, UK.
University of New South Wales and St. George Hospital, Sydney, Australia.
Hematology Project Foundation, Vicenza, Italy.
San Bortolo Hospital, Vicenza, Italy.
Hospital Juárez de México, México City, México.
Medizinische Universitat Wien, Vienna, Austria.
Amgen Inc., Thousand Oaks, CA, USA.


The thrombopoietin receptor agonist romiplostim is approved for second-line use in chronic immune thrombocytopenia (ITP), but its effects in patients with ITP for ≤1 year are not well characterized. This analysis of pooled data from 9 studies included patients with ITP for ≤1 year (n = 311) or >1 year (n = 726) who failed first-line treatments and received romiplostim, placebo or standard of care. In subgroup analysis by ITP duration, patient incidences for platelet response at ≥75% of measurements were higher for romiplostim [ITP ≤1 year: 74% (204/277); ITP >1 year: 71% (450/634)] than for placebo/standard of care [ITP ≤1 year: 18% (6/34); ITP >1 year: 9% (8/92)]. Of patients with ≥9 months on study, 16% with ITP ≤1 year and 6% with ITP >1 year discontinued romiplostim and maintained platelet counts ≥50 × 109 /l for ≥6 months without ITP treatment (treatment-free remission). Independent of ITP duration, rates of serious adverse events and bleeding were lower with romiplostim than placebo/standard of care and thrombotic events occurred at similar rates. In this analysis, romiplostim and placebo/standard of care had similar safety profiles and romiplostim increased platelet counts in patients with either ITP ≤1 year or ITP >1 year, with more treatment-free remission in those with ITP ≤1 year.


immune thrombocytopenia; newly diagnosed; persistent; romiplostim; thrombopoietin


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center